高负载纳米聚合物的定向发现,通过与药物匹配的橄酸辅助剂实现
Naxhije Berisha1,2,3,4, Atena Farahpour1,2,3,4,5, Maithreyi Ramakrishnan1,2,3,5
1Nanoscience Initiative, Advanced Science Research Center, CUNY Graduate Center, City University of New York, New York, NY 10031, USA.
概括
研究人员开发了类药物纳米颗粒,达到高达98%的药物负载,在白血病模型中显著提高了抗瘤功效. 这些设计为高效的药物输送系统提供了一种新的方法.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 药物运输 药物运输 药物运输
背景情况:
- 纳米颗粒可以增强药物的药理动力学,但往往受到药物负载效率低的影响.
- 现有的药物聚合纳米颗粒显示高负载,但需要特定的辅助物质来有效地联合组装.
- 由于其多样化的化学性质,提供了一个多功能和可生物降解的平台,用于设计新型辅助剂.
研究的目的:
- 研究类作为设计辅助剂,用于制造高负载药物纳米粒子.
- 通过调节关键结构特征来设计和选模仿已知的辅助剂的五基架.
- 在临床前癌症模型中评估类药物纳米颗粒的疗效.
主要方法:
- 设计的五基架具有不同的芳香度,刚性和电荷.
- 选了184种类药物配方,具有多种治疗性载荷.
- 利用分子动力学模拟和质谱学来阐明纳米粒子形成机制.
- 在急性髓性白血病模型中测试了含有莱斯塔乌尔提尼布的类药物配方.
主要成果:
- 在-药物纳米颗粒中达到高达98%的药物加载.
- 确定了特异性托芬-药物相互作用和充电的残留溶剂暴露作为核心结构形成的驱动因素.
- 在急性骨髓性白血病模型中,使用类药物纳米颗粒与莱斯塔乌尔提尼布的抗瘤疗效被证明是增强的.
结论:
- 寡可以合理地设计为辅助剂,以高效地与治疗性载荷一起组装.
- 使用类药物配方可以实现具有提高抗瘤功效的高负载纳米颗粒.
- 这种方法为开发先进的药物输送系统提供了一个有前途的战略.
相关概念视频
Drug Discovery: Overview
11.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.9K
Sign Test for Matched Pairs
427
The sign test for matched pairs offers a robust method for comparing two paired samples, often for the effects of an intervention in one of them. This method is very useful in situations where the underlying distribution of the data is unknown. The test compares two related samples—often pre- and post-treatment measurements on the same subjects—to determine if there are significant differences in their median values.
To conduct the sign test, we first calculate the differences in...
To conduct the sign test, we first calculate the differences in...
427
Peptide Bonds
83.5K
A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
83.5K
Antihypertensive Drugs: Direct Renin Inhibitors
1.6K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
189
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
189
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K


